Lyme Study: ACS 200® Achieves Complete Kill against Borrelia Burgdorferi
Some of the most ill people I have tried to help have been diagnosed with Lyme disease. Conventionally, the diagnostic and treatment options are not good. Serological testing has been disappointing and confusing. The use of short-term and long-term antibiotics is problematic. The alternative approach of the parenteral use of parental hydrogen peroxide and Vitamin C has provided improvement, but these agents are very harsh on the veins and poorly tolerated long-term.
The history of Lyme disease begins in 1949; Dr. Sven Hellerstrom from the Dermatological Clinic of Karolinska institute in Stockholm, Sweden presented the paper “Erythema chronicum migrans Afzelius with meningitis” at the 43rd Annual Meeting of the Southern Medical Association in Cincinnati, Ohio. He presented convincing evidence that both the erythema and subsequent meningocerebrospinal symptoms may develop following a tick bite. He also reported on the successful treatment of his patient with penicillin, a drug shown previously by his colleague Dr. Hollstrom to be effective in the treatment of Erythema chronicum migrans (ECM).
In the United States, ECM was first reported in 1970 on a physician bitten by a tick in northeastern Wisconsin. The attending physician, Dr. Rudolf Scrimenti, recognized the similarity of the patient’s skin reaction to the lesions of European ECM and successfully treated the patient with penicillin.
The treatment of three additional patients with penicillin and of one with erythromycin resulted in complete resolution of symptoms within 48 to 72 hours. Since 1972, residents in the eastern Connecticut towns of Lyme, Old Lyme, and East Haddam had been suffering from an illness characterized by recurrent attacks of asymmetric swelling and pain in large joints, especially the knee. Since such arthritic conditions were not known to be associated with ECM in Europe, the illness was thought to be a new clinical entity and was named Lyme arthritis, later changed to Lyme disease when it was determined that arthritis was only one of several manifestations of this disease.
Non-motile Borrelia by Dark Field Microscopy
Diagnosis of late-stage Lyme disease is often difficult because of the many symptoms that can mimic other diseases. Lyme disease may be misdiagnosed as multiple sclerosis, rheumatoid arthritis, fibromyalgia, chronic fatigue syndrome, lupus, or other autoimmune and neurodegenerative diseases.
The search for effective antibiotics in the treatment of Lyme disease began in 1982 with Dr. William Burgdorfer’s discovery of the spirochete now known as Borrelia burgdorferi as the causative agent of Lyme disease, ECM and related disorders (acrodermatitis chronica atrophicans, lymphadenosis benigna cutis) in Europe.
The antibiotics initially found to be effective include tetracyclines (doxycycline, minocycline), penicillins (penicillin G, amoxycillin), cephalosporins (cefotaxime, ceftriaxone), and erythromycin. Use of these drugs depends on the timeframe of diagnosis. Early Lyme disease is conventionally treated orally, whereas late Lyme disease uses parenteral or a combination of parenteral and oral applications. Treatment failures have been reported for each of these drugs particularly for the tetracyclines that are only temporarily effective unless they are applied over long periods of time, i.e. months to years. The difficulties with long-term antibiotic protocols include the expense, lack of insurance coverage, side-effects, potential for development of resistance and lack of studies demonstrating efficacy.
Due to the obvious and desperate need for an effective anti-Borrelia agent and that Advanced Cellular Silver (ACS) 200® in previous studies has been proven to be a safe and effective anti-bacterial, antiviral and anti-fungal agent, the following independent studies were conducted.
Independent studies performed by Dr. Robison at BYU generated the following kill-time data using ACS 200® against B. burgdorferi. The kill-time studies used loss of motility of the spirochetes as the kill criteria as observed via dark field microscopy. It is important to know that the Borellia kill-time protocol used for this test was originated by Dr. William Burgdorfer.
B. burgdorferi baseline count:
Mean number of motile organisms: 130/ field. The estimated volume of 1 field is approximately 3.4 x 106 ml. Therefore, the starting concentration of the B. burgdorferi culture was approximately 3.8 x 107 organisms/ml.
| ACS 200 | |
|---|---|
| Time | No. motile organisms |
| 1.5 min | 17 |
| 4 min | 1 |
| 6 min | 1 |
| 8 min | 0 |
| PSS | |
|---|---|
| Time | No. motile organisms |
| 1 min | 11 |
| 4 min | 10 |
| 6 min | 3 |
| 8 min | 10 |
Since a 1:10 dilution of the culture was performed in both the test and PSS control suspensions, the number of live organisms observed after 8 minutes in the PSS control was about 77% of that expected.
Conclusion
After years of extensive research, ACS 200® has now been shown to achieve complete kill against Borrelia Burgdorferi in only 8 minutes. These test results represent a significant feat as the Lyme disease associated microorganism is extremely difficult to culture, test and kill. Most of the B. burgdorferi motility ceased after about 4 minutes of exposure to the ACS 200® solution. No motility was observed after 8 minutes of exposure. Dr. Burgdorfer described similar in vitro testing results using a colloidal silver preparation. He surmised that silver disables the enzyme(s) used by bacterial, fungal and viral agents for their oxygen metabolism causing them to suffocate upon contact. There have been reports of elimination of late-stage Lyme symptoms using colloidal silver preparations. This data provides the scientific basis for using ACS 200® as an effective anti- Borrelia agent. In the clinical setting, many practitioners currently prescribe ACS 200® to their Lyme patients with excellent outcomes. Adding Advanced Cellular Zeolite (ACZ) nano® to reduce toxic body burden is a very powerful adjunct to the ACS 200® protocol. When taken together, these two products are highly effective in broad treatment.
Clinical Results
“I have been using the ACS 200 for well over a year and find that I rely on taking it daily. I have the Varestrongylus Klapowi worm that Lyme and CFS patients suffer with and I take 2 ounces, 3 times a week, and it has helped to get the worm under control. I also take 5 sprays by mouth, 3 times daily. ACS 200 is such an important part of my wellness program that I carry a bottle in my purse. It is also great for sinus infections, pink eye and ear infections. Make sure you hold the solution in your mouth for 3 to 5 minutes if you can. Lyme patients have severe dental problems and by holding each dose in your mouth, it helps our gums. I make sure I spray my mouth several times when out in public, especially the movie theater.” Linda H.
About the Author
Dr. Hanshew practiced medicine on the seaside of Seattle for 15 years. She achieved Board-Certified in Family Medicine and Bariatric Medicine. She also has specialized training in Anti-Aging Medicine, Natural Hormone Replacement and Environmental Toxicity issues relating to the exponential rise in the incidence and successful treatment of Autism, Fibromyalgia, ADD, Chronic Fatigue, Multiple Sclerosis, Obesity, Anxiety, Depression and Cancer.
References
1. Burgdorfer, William. “From Penicillin to Mild Silver Protein-An Answer to Lyme Disease Without Antibiotics”. Rocky Mountain Labortories, Division of N.I.H.
2. Cairns V, Godwin J (2005). “Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms”. Int J Epidemiol 34 (6): 1340–1345.
3. Singh SK, Girschick HJ (July 2004). “Lyme borreliosis: from infection to autoimmunity”. Clin. Microbiol. Infect. 10 (7): 598–614.
4. Stricker RB (July 2007). “Counterpoint: long-term antibiotic therapy improves persistent symptoms associated with Lyme disease”. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 45 (2): 149–57.
5. Klempner MS, Hu LT, Evans J, et al. (July 2001). “Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease”. N. Engl. J. Med. 345 (2): 85–92.
6. Fallon BA, Keilp JG, Corbera KM, Petkova E, Britton CB, Dwyer E, Slavov I, Cheng J, Dobkin J, Nelson DR, Sackeim HA (March 2008). “A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy”. Neurology 70 (13): 992–1003.
7. Krupp LB, Hyman LG, Grimson R, et al. (24 June 2003). “Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial”. Neurology 60 (12): 1923–30.
8. Feder HM, Johnson BJ, O’Connell S, et al. (October 2007). “A critical appraisal of “chronic Lyme disease””. N. Engl. J. Med. 357 (14): 1422–30.
9. Steere AC, Sikand VK, Schoen RT, Nowakowski J (2003). “Asymptomatic infection with Borrelia burgdorferi”. Clin. Infect. Dis. 37 (4): 528–532.
10. Fahrer H, Sauvain MJ, Zhioua E, Van Hoecke C, Gern LE (1998). “Longterm survey (7 years) in a population at risk for Lyme borreliosis: what happens to the seropositive individuals?”. Eur. J. Epidemiol. 14 (2): 117–123.
11. Smith RP, Schoen RT, Rahn DW, Sikand VK, Nowakowski J, Parenti DL, Holman MS, Persing DH, Steere AC (March 2002). “Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans”. Ann. Intern. Med. 136 (6): 421–428.
12. Auwaerter PG, Aucott J, Dumler JS (January 2004). “Lyme borreliosis (Lyme disease): molecular and cellular pathobiology and prospects for prevention, diagnosis and treatment”. Expert Rev Mol Med 6 (2): 1–22.
13. Steere AC, Dhar A, Hernandez J, et al. (January 2003). “Systemic symptoms without erythema migrans as the presenting picture of early Lyme disease”. Am. J. Med. 114 (1): 58–62.
14. Dandache P, Nadelman RB (June 2008). “Erythema migrans”. Infect. Dis. Clin. North Am. 22 (2): 235–60.Stanek G, Strle F (June 2008). “Lyme disease: European perspective”. Infect. Dis. Clin. North Am. 22 (2): 327–39.
15. Chabria SB, Lawrason J (2007). “Altered mental status, an unusual manifestation of early Disseminated Lyme disease: A case report”. Journal of Medical Case Reports 1 (1): 62.
16. Shadick NA, Phillips CB, Sangha O, et al. (December 1999). “Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease”. Ann. Intern. Med. 131 (12): 919–26.
17. Seltzer EG, Gerber MA, Cartter ML, Freudigman K, Shapiro ED (February 2000). “Long-term outcomes of persons with Lyme disease”. JAMA 283 (5): 609–16.
18. Hess A, Buchmann J, Zettl UK, et al. (1999). “Borrelia burgdorferi central nervous system infection presenting as an organic schizophrenia-like disorder”. Biol. Psychiatry 45 (6): 795.
19. Puius YA, Kalish RA (June 2008). “Lyme arthritis: pathogenesis, clinical presentation, and management”. Infect. Dis. Clin. North Am. 22 (2): 289– 300, vi–vii.
20. Mullegger RR (2004). “Dermatological manifestations of Lyme borreliosis”. Eur J Dermatol 14 (5): 296–309.
21. Tilly K, Rosa PA, Stewart PE (June 2008). “Biology of infection with Borrelia burgdorferi”. Infect. Dis. Clin. North Am. 22 (2): 217–34,
22. Lo Re V, Occi JL, MacGregor RR (April 2004). “Identifying the vector of Lyme disease”. Am Fam Physician 69 (8): 1935–7.
23. Steere AC (July 2001). “Lyme disease”. N. Engl. J. Med. 345 (2): 115–25.
24. Puius YA, Kalish RA (June 2008). “Lyme arthritis: pathogenesis, clinical presentation, and management”. Infect. Dis. Clin. North Am. 22 (2): 289–300, vi–vi.
25. Tylewska-Wierzbanowska S, Chmielewski T. (Jul 2002) “Limitation of serological testing for Lyme borreliosis evaluation of ELISA and western blot in comparison with PCR and culture methods”. Wien Klin Wochenschr 114(13- 14):601-5.
